Does the media favor MGTX or ANIK?

In the previous week, MeiraGTx had 4 more articles in the media than Anika Therapeutics. MarketBeat recorded 6 mentions for MeiraGTx and 2 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat MeiraGTx's score of 0.48 indicating that Anika Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anika Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer JANX or ANIK?

In the previous week, Janux Therapeutics had 3 more articles in the media than Anika Therapeutics. MarketBeat recorded 5 mentions for Janux Therapeutics and 2 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat Janux Therapeutics' score of 0.57 indicating that Anika Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anika Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AKTS or ANIK?

In the previous week, Aktis Oncology had 3 more articles in the media than Anika Therapeutics. MarketBeat recorded 5 mentions for Aktis Oncology and 2 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat Aktis Oncology's score of 0.58 indicating that Anika Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anika Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ANIK or SVRA?

In the previous week, Savara had 4 more articles in the media than Anika Therapeutics. MarketBeat recorded 6 mentions for Savara and 2 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat Savara's score of 0.32 indicating that Anika Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Anika Therapeutics (ANIK) Competitors

$19.58 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$19.57 -0.01 (-0.08%)

As of 10/9/2026 07:30 PM Eastern

Compare

ANIK vs. ANVS, MGTX, JANX, AKTS, and SVRA

Should you buy Anika Therapeutics stock or one of its competitors? Anika Therapeutics's main competitors and comparable companies include Annovis Bio (ANVS), MeiraGTx (MGTX), Janux Therapeutics (JANX), Aktis Oncology (AKTS), and Savara (SVRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Anika Therapeutics compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Anika Therapeutics has higher revenue and earnings than Annovis Bio. Anika Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
Anika Therapeutics	$112.82M	2.32	-$10.88M	-$0.27	N/A

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 15.9% of Annovis Bio shares are held by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Annovis Bio has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
Anika Therapeutics	-3.14%	0.20%	0.15%

Annovis Bio has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

In the previous week, Anika Therapeutics had 2 more articles in the media than Annovis Bio. MarketBeat recorded 2 mentions for Anika Therapeutics and 0 mentions for Annovis Bio. Anika Therapeutics' average media sentiment score of 1.44 beat Annovis Bio's score of 0.00 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Annovis Bio	Neutral
Anika Therapeutics	Positive

Annovis Bio currently has a consensus price target of $12.00, indicating a potential upside of 879.59%. Anika Therapeutics has a consensus price target of $22.00, indicating a potential upside of 12.36%. Given Annovis Bio's higher probable upside, analysts plainly believe Annovis Bio is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anika Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Anika Therapeutics beats Annovis Bio on 8 of the 13 factors compared between the two stocks.

How does Anika Therapeutics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

MeiraGTx presently has a consensus target price of $24.71, indicating a potential upside of 131.19%. Anika Therapeutics has a consensus target price of $22.00, indicating a potential upside of 12.36%. Given MeiraGTx's stronger consensus rating and higher possible upside, research analysts clearly believe MeiraGTx is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78
Anika Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Anika Therapeutics has lower revenue, but higher earnings than MeiraGTx. Anika Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$397.50M	2.58	-$114.20M	$0.71	15.06
Anika Therapeutics	$112.82M	2.32	-$10.88M	-$0.27	N/A

MeiraGTx has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

MeiraGTx has a net margin of 19.87% compared to Anika Therapeutics' net margin of -3.14%. MeiraGTx's return on equity of 283.85% beat Anika Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
Anika Therapeutics	-3.14%	0.20%	0.15%

In the previous week, MeiraGTx had 4 more articles in the media than Anika Therapeutics. MarketBeat recorded 6 mentions for MeiraGTx and 2 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat MeiraGTx's score of 0.48 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anika Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

MeiraGTx beats Anika Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Anika Therapeutics compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Janux Therapeutics had 3 more articles in the media than Anika Therapeutics. MarketBeat recorded 5 mentions for Janux Therapeutics and 2 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat Janux Therapeutics' score of 0.57 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anika Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Janux Therapeutics has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Anika Therapeutics	-3.14%	0.20%	0.15%

Janux Therapeutics has a beta of 2.4, suggesting that its stock price is 140% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

Janux Therapeutics presently has a consensus price target of $36.46, suggesting a potential upside of 98.27%. Anika Therapeutics has a consensus price target of $22.00, suggesting a potential upside of 12.36%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Janux Therapeutics is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Anika Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Anika Therapeutics has higher revenue and earnings than Janux Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	112.44	-$113.62M	-$1.64	N/A
Anika Therapeutics	$112.82M	2.32	-$10.88M	-$0.27	N/A

Summary

Janux Therapeutics beats Anika Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Anika Therapeutics compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Anika Therapeutics has higher revenue and earnings than Aktis Oncology. Anika Therapeutics is trading at a lower price-to-earnings ratio than Aktis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	150.09	-$63.73M	-$0.82	N/A
Anika Therapeutics	$112.82M	2.32	-$10.88M	-$0.27	N/A

Aktis Oncology has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Aktis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Anika Therapeutics	-3.14%	0.20%	0.15%

Aktis Oncology currently has a consensus target price of $35.63, suggesting a potential upside of 96.28%. Anika Therapeutics has a consensus target price of $22.00, suggesting a potential upside of 12.36%. Given Aktis Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Aktis Oncology is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Anika Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Aktis Oncology had 3 more articles in the media than Anika Therapeutics. MarketBeat recorded 5 mentions for Aktis Oncology and 2 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat Aktis Oncology's score of 0.58 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anika Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aktis Oncology and Anika Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Anika Therapeutics compare to Savara?

Anika Therapeutics (NASDAQ:ANIK) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Anika Therapeutics has higher revenue and earnings than Savara. Anika Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	2.32	-$10.88M	-$0.27	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

In the previous week, Savara had 4 more articles in the media than Anika Therapeutics. MarketBeat recorded 6 mentions for Savara and 2 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat Savara's score of 0.32 indicating that Anika Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anika Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anika Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Savara has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Savara has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
Savara	N/A	-90.28%	-68.95%

91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Anika Therapeutics presently has a consensus price target of $22.00, indicating a potential upside of 12.36%. Savara has a consensus price target of $10.25, indicating a potential upside of 108.33%. Given Savara's stronger consensus rating and higher possible upside, analysts plainly believe Savara is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Savara	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Anika Therapeutics beats Savara on 9 of the 16 factors compared between the two stocks.

Get Anika Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIK vs. The Competition

Export

Metric	Anika Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$261.98M	$3.93B	$7.25B	$13.28B
Dividend Yield	N/A	3.65%	2.52%	22.58%
P/E Ratio	-72.52	13.62	275.59	26.13
Price / Sales	2.32	1,231.40	586.27	86.30
Price / Cash	N/A	39.46	27.30	36.12
Price / Book	1.97	17.17	10.82	6.16
Net Income	-$10.88M	-$22.69M	$3.50B	$381.12M
7 Day Performance	-0.76%	-1.64%	-1.19%	-1.43%
1 Month Performance	-6.14%	-7.97%	-4.00%	-3.36%
1 Year Performance	117.07%	14.18%	7.13%	1.49%

Anika Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIK Anika Therapeutics	3.548 of 5 stars	$19.58 flat	$22.00 +12.4%	+117.1%	$261.98M	$112.82M	N/A	235	News Coverage
ANVS Annovis Bio	1.7284 of 5 stars	$1.20 -0.4%	$12.00 +904.2%	-27.9%	$51.00M	N/A	N/A	7
MGTX MeiraGTx	3.0597 of 5 stars	$10.61 -2.8%	$24.71 +132.9%	+36.4%	$1.02B	$397.50M	14.94	393	Analyst Upgrade Insider Trade
JANX Janux Therapeutics	2.5205 of 5 stars	$16.41 -0.8%	$36.46 +122.3%	-30.6%	$1.00B	$10M	N/A	113
AKTS Aktis Oncology	2.5367 of 5 stars	$18.51 -0.1%	$35.63 +92.5%	N/A	$994.64M	$6.50M	N/A	79	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIK) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anika Therapeutics (ANIK) Competitors

ANIK vs. ANVS, MGTX, JANX, AKTS, and SVRA

How does Anika Therapeutics compare to Annovis Bio?

Summary

How does Anika Therapeutics compare to MeiraGTx?

Summary

How does Anika Therapeutics compare to Janux Therapeutics?

Summary

How does Anika Therapeutics compare to Aktis Oncology?

Summary

How does Anika Therapeutics compare to Savara?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIK vs. The Competition

Anika Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anika Therapeutics (ANIK) Competitors

ANIK vs. ANVS, MGTX, JANX, AKTS, and SVRA

How does Anika Therapeutics compare to Annovis Bio?

Which has stronger valuation & earnings, ANVS or ANIK?

Do insiders & institutionals believe in ANVS or ANIK?

Is ANVS or ANIK more profitable?

Which has more risk and volatility, ANVS or ANIK?

Does the media favor ANVS or ANIK?

Do analysts recommend ANVS or ANIK?

Summary

How does Anika Therapeutics compare to MeiraGTx?

Do analysts prefer MGTX or ANIK?

Which has stronger valuation & earnings, MGTX or ANIK?

Which has more volatility & risk, MGTX or ANIK?

Is MGTX or ANIK more profitable?

Does the media favor MGTX or ANIK?

Do institutionals and insiders have more ownership in MGTX or ANIK?

Summary

How does Anika Therapeutics compare to Janux Therapeutics?

Does the media prefer JANX or ANIK?

Is JANX or ANIK more profitable?

Which has more volatility & risk, JANX or ANIK?

Do analysts rate JANX or ANIK?

Do institutionals and insiders hold more shares of JANX or ANIK?

Which has better valuation & earnings, JANX or ANIK?

Summary

How does Anika Therapeutics compare to Aktis Oncology?

Which has stronger valuation & earnings, AKTS or ANIK?

Is AKTS or ANIK more profitable?

Do analysts rate AKTS or ANIK?

Do insiders and institutionals hold more shares of AKTS or ANIK?

Does the media prefer AKTS or ANIK?

Summary

How does Anika Therapeutics compare to Savara?

Which has higher earnings and valuation, ANIK or SVRA?

Does the media refer more to ANIK or SVRA?

Which has more volatility & risk, ANIK or SVRA?

Is ANIK or SVRA more profitable?

Do institutionals and insiders have more ownership in ANIK or SVRA?

Do analysts rate ANIK or SVRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIK vs. The Competition

Anika Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools